CLDI PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

CLDI ▼ -6.28% at T+20d

NEUTRAL call ✗ call lost -6.28% · α vs SPY -18.87% · entry $0.2390 → $0.2240

Next anchor: T+60d in 11d

Currently $0.1540 · -35.56% from $0.2390 entry

Entry anchored
Mar 27, 03:59 PM ET
via Databento tick

T+1d

0.00%

call 0.00% · α -2.89%

$0.2390

settled 3mo ago

T+5d

+1.26%

call +1.26% · α -3.04%

$0.2420

settled 2mo ago

T+20d

-6.28%

call -6.28% · α -18.87%

$0.2240

settled 7w ago

T+60d

—

call — · α —

—

in 11d

Price Chart

Loading chart...

Executive Summary

Calidi Biotherapeutics reported Q4 and full-year 2025 financial results, showing a narrowed net loss per share despite a slight increase in total net loss. The company highlighted progress in advancing its CLD-401 clinical program, including FDA feedback alignment, partnerships with Avance Clinical and Matica Bio, and presentation of new in situ T-cell engager data. It raised $6.5 million in capital, extending cash runway, though cash balance declined from $9.6M to $5.6M year-over-year.

Key Financial Metrics

EPS

$-5.95

Actionable Insight

The improved EPS and new funding provide temporary relief, but the company remains in a high-burn phase with clinical milestones still years away (IND by 2026). Monitor progress toward IND submission and additional financing needs, as current cash may not be sufficient through 2026 without further raises.

Key Facts

Net loss attributable to common stockholders was $25.6M in 2025 vs $23.8M in 2024, but net loss per share improved to $5.95 from $35.70 due to higher share count.
R&D expenses increased to $9.7M in 2025 from $8.9M in 2024; G&A expenses decreased to $10.5M from $12.9M.
Cash balance declined from $9.6M (Dec 2024) to $5.6M (Dec 2025), despite $6.5M raised in Q1 2026 and Q4 2025.
Company partnered with Avance Clinical to accelerate first-in-human trial of CLD-401 in Australia and with Matica Bio for GMP manufacturing.
FDA feedback via Type D meeting supports manufacturing approach; IND filing expected by end of 2026.

Financial Impact

Net loss increased by $1.8M YoY but loss per share decreased by 83% due to share count increase. $6.5M in new funding extends runway but does not fully offset cash burn of $4.0M in 2025.

cashnet_lossepsr_and_dg_and_a

Risk Factors

Cash runway may be insufficient to reach IND filing in 2026 without additional financing.
Clinical development delays or failure to secure FDA approval could materially impact viability.
High share count increase (from 667K to 4.3M shares) indicates significant dilution for existing shareholders.

Market Snapshot

Exchange

OTC

Sector

Biological Products, (No Diagnostic Substances)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3264097

6 reports for CLDI

T+1T+5T+20T+60

33% Hit rate 1 of 3 directional calls best @ T+60▲ +53.89%Mar 10, 2026

Filters

Reports for CLDI — sortable, filterable
	Type				Now
May 26, 2026 17d ago	Press Release NEUTRAL ★ 4/10	$0.1770 $0.1840	▲ +3.95%	▲ +2.87%	$0.1540 (−12.99%)
May 22, 2026 21d ago	Press Release BEARISH ★ 7/10	$0.1770 $0.1800	▼ −1.69%	▼ −0.48%	$0.1540 (+12.99%)
Apr 20, 2026 7w ago	Press Release BULLISH ★ 7/10	$0.2500 $0.2380	▼ −4.80%	▼ −5.71%	$0.1540 (−38.40%)
Mar 27, 2026 11w ago	Press Release MIXED ★ 5/10	$0.2390 $0.2420	▲ +1.26%	▼ −3.04%	$0.1540 (−35.56%)
Mar 10, 2026 13w ago	Press Release BEARISH ★ 7/10	$0.3600 $0.3140	▲ +12.78%	▲ +11.87%	$0.1540 (+57.22%)
Mar 5, 2026 14w ago	Press Release NEUTRAL ★ 4/10	$0.3610 $0.3180	▼ −11.91%	▼ −10.38%	$0.1540 (−57.34%)

US Market Status

Market Closed — Opens Mon (49h 37m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access